CSF3 and breast carcinoma: Based on our preclinical data (Stockmeyer et al, 1997), the combination of MDX-H210 and G-CSF was analysed in a phase I study, performed in 30 heavily pretreated breast carcinoma patients overexpressing HER-2/neu.